Earnings ·
Carlsmed, Inc. reported second quarter 2026 financial results on August 5, 2026, announcing revenue of $18.9 million…
CARLCarlsmed, Inc.
Carlsmed, Inc. reported second quarter 2026 financial results on August 5, 2026, announcing revenue of $18.9 million, a 57% increase year-over-year from $12.1 million. The company raised its full-year 2026 revenue guidance to $74–$78 million, up from the previous range of $72–$77 million. Gross profit reached $14.5 million with a gross margin of 76.8%, while operating expenses increased to $25.6 million due to higher sales and marketing costs. Net loss widened to ($10.5) million compared to ($6.8) million in the prior year period, and adjusted EBITDA was ($8.6) million. The company highlighted a recent CMS ruling effective October 1, 2026, providing enhanced reimbursement for aprevo® lumbar procedures, and noted that surgeon adoption grew over 60% year-over-year. Carlsmed operates in the medical technology industry, pioneering AI-enabled personalized spine surgery solutions.